HGH Fragment 176-191
HGH Fragment 176-191
GH fragment targeting fat metabolism.
GH fragment targeting fat metabolism.
Triple GLP-1/GIP/glucagon agonist; late-stage trials.
Targeted lipolysis without GH-like side effects in preclinical models.
Dual GLP-1/glucagon agonist; phase 3 trials.
GLP-1 receptor agonist for metabolic disease and weight management.
Long-acting amylin analog; combined with semaglutide in trials.
Dual GIP/GLP-1 agonist; next-generation metabolic therapy.
Daily GLP-1 agonist for type 2 diabetes and obesity.
Once-weekly GLP-1 agonist for type 2 diabetes.
GLP-1 agonist for type 2 diabetes management.